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SUMMARY 
The regulated trafficking of neurotransmitter receptors at synapses is critical for synaptic 
plasticity. Still, the molecular machinery that controls active transport of receptors into 
synapses is largely unknown. We report that, in rat hippocampus, the insertion of AMPA 
receptors into spines during synaptic plasticity requires a specific motor protein, which 
we identify as Myosin Va. We found that Myosin Va associates with AMPA receptors 
through its cargo binding domain. This interaction is enhanced by active, GTP-bound 
Rab11, which is also transported by the motor protein. Myosin Va mediates the CaMKII-
triggered translocation of GluR1 receptors from the dendritic shaft into spines, but it is 
not required for constitutive GluR2 trafficking. Accordingly, Myosin Va is specifically 
required for long-term potentiation, but not for basal synaptic transmission. In summary, 
this work identifies the specific motor protein and organelle acceptor that catalyze the 
directional transport of AMPA receptors into spines during activity-dependent synaptic 
plasticity. 
INTRODUCTION 
The polarized trafficking and targeting of a variety of proteins, such as 
neurotransmitter receptors, ion channels, anchoring and cell adhesion molecules are 
critically important for synaptic function and plasticity. In particular, local membrane 
transport at the postsynaptic terminal is now appreciated as an important contributor to 
synaptic plasticity (see 1 for a recent review). In the case of excitatory synapses in the 
hippocampus, the postsynaptic membrane is located within micron-size dendritic 
protrusions, known as spines. Despite the small distances involved, the transport of 
specific proteins and organelles in and out of spines appears to be tightly regulated. For 
example, synaptic potentiation is accompanied by the translocation of recycling 
endosomes2 and AMPA-type glutamate receptors (AMPARs) into spines3. Conversely, 
the A-type K+ channel Kv4.2 is mobilized in the opposite direction, that is, leaves the 
spine, upon similar synaptic plasticity induction4. This dynamic behavior implies a 
carefully choreographed transport of specific cargo in a polarized manner in response to 
synaptic activity. Nevertheless, the molecular mechanisms that control this directional 
trafficking in dendritic spines remain to be discovered. 
AMPARs are responsible for most excitatory synaptic transmission in the brain, 
and their regulated addition and removal from synapses leads to long-lasting forms of 
synaptic plasticity, such as long-term potentiation (LTP) and long-term depression 
(LTD)5. Distinct AMPAR populations undergo differential synaptic trafficking depending 
on their subunit composition. Thus, AMPARs assembled as GluR2 homomers or 
GluR2/GluR3 heteromers cycle in and out of the synaptic membrane in a constitutive 
manner, which does not require synaptic activity6,7. This constitutive trafficking requires 
GluR2-specific interactions with NSF8-10. In contrast, AMPARs containing the GluR1 
subunit translocate into spines and are inserted into synapses in response to NMDA 
receptor activation during LTP3,11.. However, the molecular machinery that mediates the 
acute, unidirectional transport of GluR1 receptors into spines and synapses during LTP 
is unknown. 
F-actin is the predominant cytoskeletal element in dendritic spines. Therefore, 
actin filaments may serve as transport tracks for the delivery or removal of proteins at 
postsynaptic terminals. However, to this date, the actin cytoskeleton has been 
commonly associated with morphogenesis and structural dynamics of spines (see 12 for 
a recent review), but not with synaptic trafficking. The active transport of cargo along 
actin filaments is carried out by molecular motor proteins of the myosin family13. 
Therefore, myosin motors are attractive candidates to mediate directional trafficking of 
synaptic proteins. Some members of the myosin family have been shown to participate 
in AMPAR transport, such as Myosin VI for endocytosis14 and Myosin Vb for dendritic 
surface expression15. However, it remains to be determined whether a specific motor 
protein is involved in the synaptic delivery of AMPARs. In fact, it has been described 
that AMPARs can reach their synaptic targets by passive diffusion along the 
extrasynaptic dendritic surface16, potentially arguing against the requirement for an 
active transport process during synaptic delivery. Nevertheless, the existence of 
constitutive and activity-dependent synaptic delivery of AMPARs7 leaves open the 
possibility that these trafficking modes may have different requirements for active 
protein transport. 
Myosin Va is highly expressed in brain17 and is present in the postsynaptic 
density (PSD)18,19 as well as in light membrane fractions20. In humans, mutations in 
Myosin Va are associated with Griscelli21 and Elejalde22 syndromes, which are 
characterized by severe neurological impairments (seizures, mental retardation and 
hypotonia). In mouse, the spontaneous null mutation of Myosin Va (dilute-lethal) also 
causes severe neurological abnormalities that culminate in death 2 to 3 weeks 
postnatal17. These pathologies suggest that Myosin Va is involved in critical intracellular 
transport events required for proper neuronal function and cognition. 
Myosin Va is involved in the transport of membrane organelles in axons23, but 
little is known about its potential function in postsynaptic membrane trafficking. In the 
cerebellum of dilute-lethal mice, the spines of Purkinje cells lack smooth endoplasmic 
reticulum and inositol-1,4,5-trisphosphate receptors (IP3Rs)24,25, and LTD of parallel 
fiber synapses is abolished26. It has been previously published that synaptic function 
and plasticity at CA3-CA1 hippocampal synapses is preserved in the dilute-lethal 
mice27. However, there have been reports of multiple synaptic dysfunctions in other 
Myosin Va mutant mice28. In addition, more acute disruption of Myosin Va function with 
a dominant negative construct impairs the transport of mRNA/protein complexes into 
dendritic spines in hippocampal neurons20, suggesting that Myosin Va may play a role in 
synaptic trafficking in the hippocampus. 
In this study we have explored the role of Myosin Va in AMPAR trafficking and 
synaptic plasticity in CA1 hippocampal neurons. We have found that Myosin Va 
associates with AMPARs through its globular, cargo-binding domain. Furthermore, this 
association is enhanced by the vesicular protein Rab11. Using a combination of 
molecular biology, electrophysiology, and fluorescence imaging, we show that Myosin 
Va mediates a very distinct step in AMPAR trafficking, that is, the activity-dependent 
translocation of GluR1-containing receptors from the dendritic shaft into the spine 
compartment. Therefore, our data reveal a specialized role of Myosin Va in postsynaptic 
function, by mediating short-range vesicular transport into spines during synaptic 
plasticity. 
RESULTS 
Association between AMPARs, Myosin Va and Rab11 in neurons 
In order to identify novel interacting proteins that may regulate AMPAR function, 
we carried out a preparative immunopurification from hippocampal neuronal cultures. 
AMPARs were immunopurified with GluR2 C-terminal antibodies. Since most AMPARs 
in the hippocampus are hetero-oligomers composed of GluR1/GluR2 or GluR2/GluR3 
subunits29, this approach is expected to yield AMPAR-associated proteins irrespectively 
from receptor subunit composition. The presence of co-purified proteins was evaluated 
by SDS-gel electrophoresis and silver staining (Fig. 1a). Mass spectroscopy analysis of 
the high-molecular weight bands identified Myosin Va as one of the co-
immunoprecipitated proteins (M.W. ~217 KDa). The association between AMPARs and 
Myosin Va was confirmed using standard immunoprecipitations with antibodies against 
GluR1 and GluR2, and Western blot analysis (Fig. 1b). Interestingly, the small GTPase 
associated to recycling endosomes, Rab1130, was also found to co-precipitate with 
AMPARs. As expected, the GluR2 PDZ binding partner GRIP1 was co-precipitated, 
whereas the NMDAR subunit NR1 did not associate with Myosin Va or AMPARs under 
these conditions (Fig. 1b).  
As an independent method to test the interaction between AMPARs and Myosin 
Va, we carried out GST-pull downs with different domains of the Myosin Va C-terminus. 
As shown in Fig. 1c (left panels), the globular tail of Myosin Va (“G-tail”; cargo binding 
domain31) interacts with AMPAR subunits from hippocampal neurons, whereas the 
medial tail of Myosin V (“M-tail”, coiled-coil domain) or plain GST did not. In addition, 
pull-downs carried out with recombinant proteins expressed in COS-7 cells, indicated 
that the globular tail of Myosin Va interacts with Rab11 and with full-length GluR1, but 
not with a truncated GluR1 mutant lacking the last 30 amino acids of the C-terminus 
(GluR1-Δ30; Fig. 1c, middle panels). And finally, His-tag-purified GluR1 C-terminus (last 
50 amino acids) was also pulled-down by the globular tail of Myosin Va (Fig. 1c, right 
panels), strongly suggesting that there is a direct interaction between these two 
proteins. In conclusion, these combined data indicate that AMPARs and Myosin Va 
associate in neurons, and that this complex is mediated by a direct interaction between 
the cargo binding domain of Myosin Va and the C-terminal 30 amino acids of GluR1. 
To further evaluate the association between AMPARs and Myosin Va, we carried 
out immunolabeling analyses of the endogenous proteins in dendrites from hippocampal 
neurons. Myosin Va shows a partial co-localization with GluR1 and GluR2 subunits in 
primary neuronal cultures (Fig. 2a,b). In many instances, though, Myosin Va appeared 
to localize adjacent to AMPAR puncta (see high-magnification insets in lower panels). 
We also examined the subcellular distribution of endogenous Myosin Va in dendrites 
and spines from CA1 neurons in hippocampal slices. Myosin Va was mostly localized at 
dendritic shafts, as compared with the enrichment of actin and PSD95 at spines (Fig. 
2c,d; see high-magnification insets in right panels). These observations are consistent 
with the previously reported partial co-localization between Myosin Va and PSD95 in 
primary neuronal cultures19. 
 
Interference with Myosin Va depresses synaptic responses 
In order to start evaluating a potential role of Myosin Va in AMPAR trafficking 
and/or synaptic plasticity, we overexpressed the cargo binding domain (globular tail) of 
Myosin Va in CA1 hippocampal neurons. This domain displaces endogenous Myosin Va 
from its tail-associated cargo31, therefore acting as a dominant negative construct 
(Myosin Va-dn). This experimental strategy has been employed on multiple occasions 
to interfere with Myosin Va-dependent trafficking. Importantly, this approach is specific 
enough to distinguish distinct functions of the three different Myosin V isoforms: Va, Vb 
and Vc15,32,33. 
We expressed GFP-fusion proteins of Myosin Va-dn, Myosin Vb-dn or Myosin VI-
dn in CA1 hippocampal neurons from organotypic slice cultures, as described in 
Methods. The effect of these dominant negative proteins on synaptic transmission was 
evaluated by simultaneous double whole-cell recordings form pairs of nearby infected 
and uninfected neurons, under voltage clamp. Myosin Va-dn produced a small but 
significant depression of AMPAR- and NMDAR-mediated currents, as compared to 
uninfected cells, while GABAA receptor-mediated inhibitory currents were unchanged 
(Fig. 3a−c; left-most panels). Neither Myosin VI-dn (Fig. 3a, middle panels) nor Myosin 
Vb-dn (Supplementary Fig. 1) significantly affected AMPAR-mediated transmission. To 
note, Myosin Va-dn did not affect the expression levels nor phosphorylation stage of 
multiple synapse-associated proteins (Supplementary Fig. 2). Therefore, these results 
suggest that Myosin Va plays a role in AMPAR synaptic function, which is not shared by 
other myosin isoforms. 
Hippocampal slices in culture exhibit spontaneous activity, which can drive 
AMPARs into synapses34. To determine whether the depression of AMPAR responses 
induced by Myosin Va-dn is dependent on spontaneous activity, we performed double 
whole-cell recordings from slices in which spontaneous activity was blocked with high 
Mg2+ (12 mM MgCl2) or the sodium channel blocker tetrodotoxin (1 μM) during the 
expression of the recombinant protein34 (slices are returned to the standard solution 
during the recordings; see Methods). Under these conditions Myosin Va-dn failed to 
depress AMPAR or NMDAR transmission (Fig. 3a,b; two right-most panels), suggesting 
that Myosin Va plays a specific role in activity-dependent regulation of synaptic function. 
Interestingly, these results also suggest that there is an activity- dependent co-scaling 
between AMPA and NMDA receptor-mediated synaptic transmission, as it has been 
previously observed in response to spontaneous synaptic activity35.. 
Although these dominant negative constructs were expressed in postsynaptic CA1 
neurons, we wanted to examine whether Myosin Va-dn may be retrogradely interfering 
with presynaptic mechanisms. To this end, we measured paired pulse facilitation (PPF), 
as an indicator of presynaptic function, from Myosin Va-dn-infected and uninfected CA1 
neurons in hippocampal slices. As shown in Fig. 3d, PPF was unaltered by Myosin Va-
dn expression. These results confirm that the depression of synaptic transmission 
observed with Myosin Va-dn is not due to alteration of presynaptic properties, and 
suggest that Myosin Va plays an independent postsynaptic role at excitatory 
hippocampal synapses. 
 
Myosin Va is required for LTP and GluR1 synaptic delivery 
AMPARs continuously cycle in and out of synapses in an NSF-dependent 
manner9,10. Our observation that Myosin Va-dn does not affect basal transmission in the 
absence of spontaneous neuronal activity suggests that Myosin Va is not involved in 
this constitutive trafficking. In order to directly test this interpretation, we carried out 
intracellular infusion experiments with a short peptide that interferes with the GluR2-
NSF interaction. This peptide has been shown to produce a fast “run-down” of synaptic 
transmission9,10, as AMPARs are continuously internalized but fail to be reinserted at 
the synaptic membrane. Neurons expressing Myosin Va-dn displayed virtually identical 
“run-down” of synaptic transmission as uninfected neurons (Fig. 4a,b). As control, a 
peptide that does not bind NSF, pep4c9, did not produce “run-down” of transmission 
(Fig. 4b). Therefore, these results confirm our interpretation that Myosin Va is not 
required for the constitutive synaptic trafficking of AMPARs. 
In order to investigate more directly whether Myosin Va is involved in the activity-
dependent delivery of AMPARs into synapses, we evaluated the effect of Myosin Va-dn 
in long term potentiation (LTP) in CA1 hippocampal neurons. Hippocampal slices were 
infected with Myosin Va-dn and were incubated with high Mg2+ to block spontaneous 
activity during the expression time. Importantly, NMDA and AMPA receptor currents are 
not affected by the recombinant protein under these conditions (Fig. 3a,b, right-most 
panels), and therefore, we can directly evaluate the effect of Myosin Va-dn in LTP 
expression without interfering with LTP induction. After 14 h, slices were transferred to 
normal extracellular solution (see Methods) and LTP was induced on infected and 
uninfected CA1 neurons by pairing presynaptic stimulation (3 Hz, 1.5 min) with 
postsynaptic depolarization (0 mV; see Methods). As shown in Fig. 4c,d, uninfected 
neurons showed a robust, 2.5-fold potentiation of transmission. In contrast, LTP was 
virtually abolished in Myosin Va-dn-expressing neurons. To note, Myosin Va-dn did not 
have any effect on the non-potentiated (control) pathway (Fig. 4d). 
As an alternative method to test the role of Myosin Va in LTP, we used an RNA 
interference approach. A small interference RNA (siRNA) was designed against the rat 
Myosin Va mRNA (see Methods for construct details). This siRNA was shown to 
effectively down-regulate the expression of recombinant Myosin Va in transfected COS-
7 cells, and of endogenous Myosin Va in hippocampal neurons (Supplementary Fig. 
3). To test the role of endogenous Myosin Va in LTP, we expressed the anti-Myosin Va 
siRNA in CA1 hippocampal neurons for three days while blocking spontaneous activity 
with tetrodotoxin. Slices were then transferred to regular recording solution and LTP 
was induced as described above. As shown in Fig. 4c,d, knock-down of Myosin Va with 
siRNA virtually abolished synaptic potentiation. Therefore, these combined results using 
Myosin Va-dn and siRNA strongly suggest that Myosin Va is critically required for LTP. 
In the hippocampus, expression of LTP is mediated by synaptic addition of GluR1-
containing AMPA receptors into synapses11. To specifically investigate the role of 
Myosin Va on the synaptic delivery of GluR1 AMPA receptors, we used the biolistic 
system to co-transfect CA1 hippocampal neurons with GFP-GluR1 and constitutively 
active CamKII (tCamKII), previously shown to mimic LTP and drive GluR1 to 
synapses11. Delivery of GFP-GluR1 receptors to synapses is monitored using the 
inward rectification properties of the homomeric recombinant receptor 
(electrophysiological tagging11,36). Synaptic delivery is then quantified as an increase in 
the ratio of the evoked postsynaptic current at -60 mV relative to the current at +40 mV 
(rectification index, RI=I-60/I+40). Co-expression of GluR1 and tCamKII produced a 
significant increase in the rectification index as compared to untransfected cells (Fig. 
4e; see also 11). In contrast, co-expression of Myosin Va-dn together with GluR1 and 
tCamKII completely blocked the increase in rectification (Fig. 4e). Similar results were 
obtained by knocking-down Myosin Va with RNA interference, that is, anti-Myosin Va 
siRNA abolished the increase in rectification while a control scrambled siRNA did not 
(Fig. 4f). These results strongly suggest that synaptic delivery of GluR1 induced by 
CamKII is mediated by Myosin Va. 
PSD95 overexpression can also drive the insertion of GluR1 into hippocampal 
synapses37. Therefore, we tested whether PSD95-driven delivery of GluR1 requires 
Myosin Va function. As expected, co-transfection of GluR1 with PSD95 lead to an 
increase of the rectification index (Supplementary Fig. 4a), indicating delivery of 
recombinant GluR1 into synapses (see also 37). Interestingly, Myosin Va-dn also 
blocked this delivery (Supplementary Fig. 4b). 
In conclusion, these combined data using dominant negative and RNA interference 
approaches indicate that Myosin Va is required for all tested forms of regulated synaptic 
delivery of GluR1: LTP induction, CaMKII activation and PSD95 overexpression. 
Therefore, Myosin Va appears to be a central factor for the activity-dependent transport 
of AMPARs into synapses. 
 
Myosin Va is not required for dendritic AMPAR transport 
The presence of Myosin Va at spines and the PSD raises the possibility that 
Myosin Va transports AMPARs locally at synapses. However, we have found that 
Myosin Va is mostly localized in dendrite shafts (Fig. 2c,d), where it could transport 
organelles involved in the dendritic trafficking of AMPARs. To determine the specific 
step mediated by Myosin Va in the transport of AMPARs, we co-transfected organotypic 
hippocampal slices with RFP-tagged Myosin Va-dn, Myosin Vb-dn or plain RFP (as 
control) together with GFP-tagged AMPAR subunits (tCaMKII was also co-expressed 
with GFP-GluR1 in some of the cells, as indicated) (Fig. 5a,d). The efficiency of the 
dendritic transport of AMPARs was quantified from the fluorescence intensity of the 
GFP-tagged receptor along the primary apical dendrite, and plotted as a function of the 
distance from the cell body36. GFP fluorescence is normalized to the maximum value at 
the cell body, to control for variability in expression levels. 
As shown in Fig. 5b (GluR1) and e (GluR2), neither Myosin Va- nor Myosin Vb-dn 
affected the distribution of GFP-tagged receptors along dendrites. Specifically, AMPAR 
expression at distal dendrites was not altered by either dominant negative construct 
(Fig. 5c,f) (tCaMKII did not affect distal GluR1 expression either; Fig. 5c, compare blue 
and black columns). In contrast, incubation of the slices with a low concentration of the 
microtubule destabilizer vincristine did significantly impair the dendritic distribution of 
GFP-tagged GluR2 (Fig. 5d−f). (To note, overexpression of the C-tail of Myosin Vb has 
been previously reported to impair GluR1 export into dendrites15; however, the tail 
domain used in that study contains additional sequences not present in the Myosin Vb-
dn globular tail used here). In conclusion, these results indicate that Myosin Va is not 
required for the long-range dendritic transport of AMPARs. 
 
Myosin Va transports GluR1 from dendritic shaft into spine 
To investigate the role of Myosin Va in the local transport of AMPARs into spines, 
we carried out confocal imaging experiments to monitor receptor distribution between 
spines and the adjacent dendritic shaft. Similar to the experiments described above, we 
co-expressed RFP-tagged Myosin Va or Vb dominant negatives (or plain RFP, as 
control) with GFP-tagged GluR1 or GluR2 subunits. The translocation of GluR1 into 
spines is an activity-dependent process3, which can be mimicked by CaMKII 
activation38. Therefore, in some of these experiments we expressed GFP-GluR1 
together with constitutively active αCaMKII (tCaMKII). 
The accumulation of AMPARs into spines was quantified from the GFP 
fluorescence intensity across the spine head and the adjacent dendritic shaft36. Data are 
then plotted normalized to the average dendrite fluorescence (Fig. 6b,e) or as 
cumulative distributions of spine/dendrite ratios (Fig. 6c,f). As previously observed38, 
tCamKII significantly increased the levels of GFP-GluR1 in spines (Fig. 6b, compare 
ligh-gray and black columns; Fig. 6c, compare dashed and black lines). Interestingly, 
addition of Myosin Va-dn completely blocked this effect, to the point that GFP-GluR1 
levels at spines were similar to those in the absence of tCaMKII (Fig. 6b, compare ligh-
gray and red columns; Fig. 6c, compare dashed and red lines). Importantly, Myosin Vb-
dn co-expressed with GFP-GluR1 and tCamKII did not affect CamKII-mediated delivery 
of GluR1 receptors into spines (Fig. 6b, compare black and dark-gray columns; Fig. 6c, 
compare black and gray lines). Therefore, these data indicate that Myosin Va is 
required for the CaMKII-driven transport of GluR1 receptors into spines. To note, 
Myosin Va-dn also decreased the fraction of GFP-GluR1 present in spines in the 
absence of tCaMKII (Fig. 6b, compare first and last spine columns). This result would 
be consistent with a basal level of GluR1 delivery into spines due to spontaneous 
activity in the slice culture. 
To determine whether Myosin Va is specifically required for the regulated transport 
of AMPARs, we carried out similar experiments with GFP-GluR2, which is inserted into 
spines in a constitutive manner, independent from synaptic activity7,38. As shown in Fig. 
6d−f, co-expression of Myosin Va-dn or Myosin Vb-dn did not impair the translocation of 
GFP-GluR2 into spines in CA1 hippocampal neurons (to note, Myosin Va-dn did 
produce a slight accumulation of GFP-GluR2 in spines, which was statistically 
significant). 
These data strongly suggest that Myosin Va specifically mediates the regulated 
translocation of GluR1 AMPARs into spines, but it is not required for the constitutive 
entry of GluR2 receptors. This morphological analysis correlates very well with our 
electrophysiology data (Figs. 3 and 4), supporting the interpretation that Myosin Va is 
specifically engaged for the activity-dependent delivery of AMPARs into synapses, but 
not for their constitutive cycling. 
 
Myosin Va is not required for spine morphology 
PSD95 is an important synaptic scaffolding protein, which can associate with 
Myosin Va via GKAP and dynein light chain (DLC) interactions18. Our data shows that 
Myosin Va-dn blocks the synaptic delivery of GluR1 receptors mediated by PSD95 
(Supplementary Fig. 4). Therefore, we decided to test whether Myosin Va plays a role 
in the targeting of PSD95 to spines. To this end, we co-expressed PSD95-GFP and 
RFP-Myosin Va-dn (or RFP, as control) in CA1 neurons from organotypic hippocampal 
slices. Distribution of PSD95-GFP in dendrites and spines was quantified as described 
above. As expected, PSD95 was highly concentrated in spines (Fig. 7a,b). Importantly, 
Myosin Va-dn did not alter the accumulation of PSD95-GFP into spines (Fig. 7a−c). 
Therefore, the blockade of PSD95-driven delivery of GluR1 to synapses by Myosin Va-
dn (Supplementary Fig. 4) is not due to an impairment of PSD95 targeting into spines. 
It has been recently shown that other members of the myosin family, such as 
Myosin VI and Myosin IIB, play critical roles in spine morphology and dynamics, and 
consequently, in synaptic function14,39. Therefore, we tested whether Myosin Va-dn may 
alter spine size or density in CA1 hippocampal neurons. To this end, we co-expressed 
cytosolic GFP (as a volume-filling indicator) with RFP-Myosin Va-dn or with RFP as a 
control. GFP fluorescence across dendrites and spine heads was calculated as 
described above. As shown in Fig. 7d,e, GFP fluorescence in spines was not altered by 
Myosin Va-dn expression, indicating that spine volume is not affected by impairing 
Myosin Va function. 
The effects of Myosin Va-dn on spine length or density were evaluated by co-
expressing PSD95-GFP, as a spine marker, with RFP-Myosin Va-dn or RFP in CA1 
hippocampal neurons, as described above. Confocal images were then analyzed using 
Neurolucida software. Spine length was determined from the peak of PSD95-GFP 
fluorescence to the center of the dendritic shaft, visualized from the RFP fluorescence. 
As shown in Fig. 7f,g, Myosin Va-dn did not alter spine length or density. Therefore, 
these data indicate that, in contrast to Myosin IIB and Myosin VI, Myosin Va does not 
play a direct role in the maintenance of spine morphology in CA1 hippocampal neurons. 
 
 
 
Rab11 couples AMPARs with Myosin Va 
Recent studies have found that recycling endosomes are mobilized into spines2 
and supply AMPARs for synaptic delivery40 during LTP. In addition, we have observed 
that Rab11, the small GTPase that controls recycling endosomal trafficking30, 
associates with AMPARs and Myosin Va (Fig. 1b,c), and is required for receptor 
translocation into spines during LTP41. Therefore, Rab11-driven recycling endosomes 
appear to be the vesicular carriers for AMPAR delivery into spines. To determine 
whether Myosin Va is involved in the transport of these recycling endosomes, we 
evaluated the effect of Myosin Va-dn on the spine localization of Rab11. CA1 
hippocampal neurons were co-transfected with GFP-Rab11 and RFP-Myosin Va-dn, or 
RFP as control. As shown in Fig. 8a,b, Myosin Va-dn produced a small, but significant, 
impairment in the spine accumulation of GFP-Rab11. These results suggest that Myosin 
Va is involved in the transport of recycling endosomes into spines. In addition, the 
modest magnitude of the shift in Rab11 spine distribution produced by Myosin Va-dn 
may imply that only a fraction of Rab11-containing endosomes are transported by 
Myosin Va. 
Rab GTPases are crucial organizers of intracellular membrane trafficking in 
eukaryotic cells. Due to their ability to interact with multiple effectors, Rab GTPases 
have been proposed to act as “organelle receptors” that would couple motor proteins 
with specific cargo for directional membrane transport13,42. Importantly, Rab GTPases 
interact with motor proteins only in their active (GTP-bound) conformation43. Based on 
our observations on the effect of Myosin Va-dn on the transport of AMPARs and Rab11 
into spines, we tested whether Rab11 could modulate the interaction between AMPARs 
and Myosin Va. 
To this end, we separately expressed GFP-fusion proteins of GluR1, Myosin Va 
globular tail (containing the cargo binding domain) and Rab11 in BHK cells. Whole-cell 
extracts in the presence of detergent were then prepared, and mixed in different 
combinations to test the effect of Rab proteins on the interaction between GluR1 and 
Myosin Va. The association between GluR1 and Myosin Va was evaluated by co-
immunoprecipitation using an anti-GluR1 antibody, in the presence of GDP or a non-
hydrolysable GTP-analog (GMP-PNP; Sigma). The specificity of the interaction was 
evaluated by substituting GFP-GluR1 with GFP. As shown in Fig. 8c (representative 
example of four independent experiments), the association between Myosin Va and 
GluR1 was weak but detectable in the absence of added Rab protein (compare lanes 1 
and 2). Interestingly, this interaction was enhanced by adding Rab11 (compare lanes 2 
and 4), but only in the presence of non-hydrolysable GTP (compare lanes 4 with 6). 
These results indicate that active Rab11 (GTP-bound) facilitates Myosin Va binding to 
GluR1, suggesting that Rab11 may act as the vesicular link that couples AMPARs and 
Myosin Va during their transport into spines. 
DISCUSSION 
 
In this study we show that Myosin Va, an actin-based motor protein present at 
synaptic sites, mediates the transport of organelles that carry AMPARs into spines in an 
activity-dependent manner. Using an unbiased biochemical approach, we identified 
Myosin Va as an interacting partner for AMPARs in hippocampal neurons. We also 
determined that this association occurs through a direct interaction between the GluR1 
C-terminus and the globular tail of Myosin Va, which is the cargo binding domain of the 
motor protein. Using electrophysiological assays on hippocampal slices, we determined 
that Myosin Va function is required for LTP and for GluR1 synaptic delivery triggered by 
CaMKII activation or by PSD95 overexpression. Importantly, the synaptic trafficking of 
AMPARs appears to be specifically carried out by Myosin Va, since blockade of other 
myosin isoforms, such as Myosin Vb and Myosin VI, did not alter AMPAR-mediated 
synaptic transmission. In addition, using confocal fluorescence imaging, we find that 
Myosin Va mediates a very precise transport step: the short-range translocation of 
GluR1-containing AMPARs from the dendritic shaft into the spine head. In contrast, 
Myosin Va is nor required for the long-range trafficking of receptors along dendrites, nor 
for the constitutive entry of GluR2 receptors into spines. And finally, we have identified 
the small GTPase Rab11 as a vesicular carrier that couples Myosin Va with its AMPAR 
cargo. Therefore, these combined results support the notion that Myosin Va is a critical 
player in the regulation of synaptic activity, which may be related to the cognitive and 
neurological deficits associated to Myosin Va mutations in humans. 
It is worth noting that a previous study did not find any deficits in hippocampal 
synaptic function or plasticity in a spontaneous mouse mutant lacking Myosin Va (dilute-
lethal)27. However, our data using both dominant negative approaches and siRNA 
knock-down indicates that Myosin Va is required for LTP in CA1 hippocampal neurons. 
We cannot be certain of the reason for this discrepancy, but it may be related with the 
acute blockade of Myosin Va function in our system (15 hours for dominant negative 
expression or 3 days for RNA interference) versus the chronic absence of Myosin Va 
during development and postnatal life in the dilute-lethal mice. 
A critical conclusion from our work is that Myosin Va is specifically required for the 
regulated transport of AMPA receptors, but not for their constitutive (activity-
independent) trafficking. Myosin Va activity is tightly controlled by intracellular calcium 
levels44. In the absence of calcium, Myosin Va adopts a compact, inactive conformation 
in which the cargo binding domain folds back on the motor domain, rendering Myosin 
Va incompetent for transport. Upon calcium binding, Myosin Va undergoes a large 
conformational change, opening into an extended, active configuration44. This calcium 
regulation of Myosin Va activity is obviously reminiscent of the long-established 
requirement of postsynaptic calcium for LTP expression45. Therefore, it is tempting to 
speculate that the rise in intracellular calcium upon NMDAR activation may constitute a 
direct link between LTP induction and the triggering of Myosin Va-dependent organelle 
transport. Alternatively, the transport machinery may stay constitutively active while LTP 
regulates the competency of GluR1 to interact with it (perhaps through GluR1 
phosphorylation and/or binding to adaptor proteins) (see model in Supplementary Fig. 
5). 
Here we propose that Rab11 mediates the association of Myosin Va with its 
AMPAR cargo. The concept of Rab proteins as organelle acceptors that couple specific 
motor proteins to cargo vesicles is not new13,42. However, this is the first time that the 
Rab11-Myosin Va pairing is reported. In fact, the motor protein typically associated to 
Rab11-dependent trafficking is Myosin Vb32, as it has been described for the export of 
AMPARs from the cell soma into dendrites15. However, our combined 
electrophysiological and imaging data indicate that Myosin Vb is not involved in the 
synaptic transport of GluR1. The unexpected coupling between Myosin Va and Rab11 
that we describe may be a functional consequence of the recruitment of Rab11-driven 
endosomes in activity-dependent trafficking within spines2,41, together with the 
specialization of Myosin Va for acute, regulated exocytic transport. 
Finally, several mechanochemical properties of Myosin Va make it an ideal motor 
to mediate the specific transport event we are proposing here. First, receptor insertion 
into spines implies a switch from the microtubular cytoskeleton present along dendrites 
towards the actin filaments enriched in spines. Interestingly, Myosin Va is able to bridge 
across microtubule and actin cytoskeletons by virtue of separate interactions with actin 
(through its N-terminal motor domain) and with tubulin (through its C-terminal cargo 
binding domain)46. In fact, Myosin Va has been shown to passively diffuse along 
microtubules47. In agreement with this transitional role between different cytoskeletal 
elements, the cargo binding domain of Myosin Va directly binds kinesin31,48, a 
microtubule-dependent motor protein. Second, Myosin Va is flexible enough to step 
over or to switch filaments at intersections and branching points in the actin 
cytoskeleton47. This property should facilitate maneuvering cargo across the intricate 
cytoskeletal meshwork of the spine. And third, Myosin Va is a processive motor, in 
contrast for example, to Myosin II49. The dimensions of a single processive run by 
Myosin Va (40 to 50 steps, approximately 1.5 μm) fit very well with the average spine 
length, and therefore with the travel distance required to transport organelles from the 
dendritic shaft into the spine head. 
 In conclusion, this work offers new insights into the molecular machinery that 
organizes membrane trafficking at postsynaptic terminals, and proposes a specific 
motor protein (Myosin Va) and its organelle acceptor (Rab11) to drive the directional 
transport of AMPARs during synaptic plasticity. 
METHODS 
Constructs of recombinant proteins and expression 
The C-terminal sequences (globular tails) of mouse Myosin Va (amino acids 1473 
to 1880), rat Myosin Vb (amino acids 1436 to 1846) and human Myosin VI (amino acids 
835 to 1285) were cloned upstream of the coding sequence for EGFP (Clontech) or a 
red fluorescent protein variant (tdimer236). Myosin Va GST constructs were generated in 
pGEX4T-3 using amino acids 1396-1830 (globular tail) and 1152-1395 (media tail) from 
rat Myosin Va. The GFP-tagged AMPAR subunits, PSD95 and the truncated CaMKII 
constructs were made as previously described7,37. The anti-Myosin Va small interference 
RNA (MyoVa siRNA) corresponds to nucleotides 5344 to 5362 in the rat Myosin Va 
mRNA (accession number AB035736). A scrambled siRNA was used as control 
(GGTTTCGTACTTTCTCTTA). siRNAs were cloned into pSuper vector for expression in 
COS-7 cells and neurons. Organotypic cultures of hippocampal slices were prepared 
from P5-6 rats and recombinant proteins were expressed using Sindbis virus or biolistic 
gene delivery (“gene gun”; Bio-Rad)36. Protein expression was typically for 14 hours or 
for 2.5 days when expressing AMPAR subunits. siRNAs were expressed in hippocampal 
slices for 3-4 days. All biosafety procedures and animal care protocols were approved 
by the University of Michigan Committee on Use and Care of Animals (UCUCA). 
 
Co-immunopurification and GST pull-downs 
Hippocampal neurons plated on coverslips coated with poly-D-lysine (30 μg/ml) and 
laminin (2 μg/ml) at a density of 300,000/well were washed once with PBS (containing 1 
mM MgCl2 and 0.1 mM CaCl2) and incubated for 1 hour at 4°C with a buffer containing 
50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% saponin and a 
protease inhibitor cocktail (“Complete EDTA-free”, Roche). For immunopurification 
experiments the soluble extracts of neurons were loaded on a column of CNBr-
Sepharose 4B resin bound to polyclonal antibody against GluR2 subunit and incubated 
overnight at 4°C. The column was washed with PBS (0.1% saponin, 0.1% Triton X-100). 
The complexes associated to GluR2 were eluted with 0.2 M glycin, pH 2.2. The co-
immunoprecipitation experiments from neurons were performed as described50. For GST 
pulldown experiments, 200 μg of soluble extracts were incubated with glutathione 
sepharose 4B (Amersham Pharmacia Biotech) coupled to 5-10 μg of GST or GST fusion 
(approximately 5 μl of bed volume) for 2 hr at 4°C, followed by four washes in PBS 
(0.1% Triton X-100). These samples were then washed and immunoprecipitated 
proteins were eluted by boiling in 1x Laemmli sample buffer and separated by SDS-
PAGE. Visualization of immunoprecipitated proteins was done by Western Blot with anti-
GluR1, -GluR2/3,–Myosin Va, -myc, -GFP or -His antibodies. 
 
Electrophysiology 
Voltage-clamp whole cell recordings were obtained from nearby infected and 
uninfected CA1 pyramidal neurons, under visual guidance using fluorescence and 
transmitted light illumination. External solution contained 119 mM NaCl, 2.5 mM KCl, 1 
mM NaH2PO4, 11 mM glucose, 26 mM NaHCO3, 4 M MgCl2, 4 mM CaCl2 and 2 μM 2-
chloroadenosine, at pH 7.4, and was gassed with 95% O2 and 5% CO2. Patch recording 
pipettes (4-7 MΩ) were filled with internal solution containing 115 mM CsMeSO3, 20 mM 
CsCl, 10 mM HEPES, 2.5 mM MgCl2, 4 mM Na2-ATP, 0.4 mM Na-GTP, 10 mM sodium 
phosphocreatine, 0.6 mM EGTA and 0.1 mM spermine, pH 7.25. In experiments with 
intracellular perfusion of peptides (pep2m or pep4c, Tocris; 1 mM final concentration), 
the internal solution was supplemented with protease inhibitors leupeptin and pepstatin 
(100 μM each). Bipolar stimulating electrodes were placed over Schaffer collateral fibers 
between 250 and 300 μm from the CA1 recorded cell, and synaptic responses were 
evoked with single voltage pulses (200 μs, up to 30 V). Synaptic AMPAR-mediated 
responses were acquired at -60 mV. NMDAR responses were recorded at +40 mV at a 
latency at which AMPAR responses have fully decayed (60 ms after stimulation). In 
both cases, 100 μM picrotoxin was present in the external solution. GABAA responses 
were acquired at 0 mV in the absence of receptor antagonists; therefore, they should be 
considered as a combination of mono- and disynaptic IPSCs. For rectification studies, 
AMPAR responses were recorded at -60 mV and +40 mV in the presence of 0.1 mM 
DL-2-amino-5-phosphonovaleric acid in the external solution. LTP was induced using a 
pairing protocol, by stimulating Schaffer collateral fibers at 3 Hz for 1.5 min, while 
depolarizing the postsynaptic cell at 0 mV. Because only CA1 cells (and not CA3 cells) 
are infected, this configuration ensures that recombinant proteins are always expressed 
exclusively in the postsynaptic cell. Whole-cell recordings were made with a Multiclamp 
700A amplifier (Axon Instruments).  
 
Fluorescence imaging 
 Immunofluorescence and imaging experiments were carried out as described in 
the Supplementary Information and 36. 
 
In vitro binding of AMPARs, Myosin Va and Rab11 
BHK cells were infected with GFP tagged Myosin Va-dn, Rab11, GluR1 or soluble 
GFP. Cells were then homogeneized in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM 
ATP, 10 mM NaF, 1 μM Microcystin LR, 0.5 μM Calyculin A, 10 mM EDTA, 0.1 mM 
PMSF, 2 μg/ml CLAP (cocktail of Chymostatin, Leupeptin, Pepstatin A and Antipain), 
0.5% Sodium Deoxycholate and 1% Nonidet P-40. Extracts were then mixed in the 
presence of 30 mM MgCl2, and 0.1 mM GMP-PNP or 1 mM GDP, as indicated. 
Immunoprecipitates were obtained by incubation of 2 µg of anti-GluR1 polyclonal 
antibody with 60 μl of protein G-sepharose beads (50%), for 4 hours at 4°C. These 
samples were then washed and immunoprecipitated proteins were eluted by boiling in 
1x Laemmli sample buffer and separated by SDS-PAGE. Visualization of 
immunoprecipitated proteins was done by Western Blot with anti-GFP antibodies 
(Roche). 
 
Statistical analyses 
Statistical significance was determined by the Kolmogorof-Smirnov test for 
cumulative distributions. When comparing mean values, statistical significance was 
determined by the Mann-Whitney test if only two distributions are being compared, or by 
ANOVA followed by a Kruskal-Wallis test, if multiple distributions are analyzed. 
AUTHOR CONTRIBUTION 
S.S.C. is responsible for most of the experimental work and wrote part of the 
manuscript. S.B carried out the biochemical experiments of Fig. 1 and the 
immunocytochemistry in Fig. 2a,b. T.C.B. contributed some of the electrophysiology and 
imaging experiments. M.-F.L. developed and characterized the siRNA used in this 
study. D.S.B. carried out some of the initial cloning of this project. A.E.-H., M.P. and 
J.A.E. designed and supervised the experiments carried out by S.B., M.-F.L. and 
S.S.C., respectively. J.A.E. coordinated the study and wrote most of the manuscript. 
 
ACKNOWLEDGEMENTS 
We thank Vladimir Gelfand and Ron Holz for the plasmid containing the mouse Myosin 
Va globular tail; David Wells and Mark Mooseker for the human Myosin VI; Yoshiko 
Takagishi for the chicken full-length Myosin Va; Sang Lee for letting us test an 
unpublished siRNA against Myosin Va (different from the one shown in this study); and 
Robert Malinow for the PSD95 construct. We also thank Lois Weisman, Miriam Meisler 
and Ron Holz for their comments on this work. This work was supported by grants from 
the National Institute of Mental Health (MH070417 to J.A.E. and F31-MH070205 to 
T.C.B.), Fundação para a Ciência e a Tecnologia (SFRH/BPD/14620 to S.S.C.) and 
Telethon-Italy (SYNSCAF project to M.P.). 
REFERENCES 
1. Kennedy, M.J. & Ehlers, M.D. Organelles and trafficking machinery for postsynaptic 
plasticity. Annu Rev Neurosci 29, 325-62 (2006). 
2. Park, M. et al. Plasticity-induced growth of dendritic spines by exocytic trafficking 
from recycling endosomes. Neuron 52, 817-30 (2006). 
3. Shi, S.H. et al. Rapid spine delivery and redistribution of AMPA receptors after 
synaptic NMDA receptor activation. Science 284, 1811-6 (1999). 
4. Kim, J., Jung, S.C., Clemens, A.M., Petralia, R.S. & Hoffman, D.A. Regulation of 
dendritic excitability by activity-dependent trafficking of the a-type k(+) channel 
subunit kv4.2 in hippocampal neurons. Neuron 54, 933-47 (2007). 
5. Shepherd, J.D. & Huganir, R.L. The cell biology of synaptic plasticity: AMPA 
receptor trafficking. Annu Rev Cell Dev Biol 23, 613-43 (2007). 
6. Passafaro, M., Piech, V. & Sheng, M. Subunit-specific temporal and spatial patterns 
of AMPA receptor exocytosis in hippocampal neurons. Nat Neurosci 4, 917-26 
(2001). 
7. Shi, S., Hayashi, Y., Esteban, J.A. & Malinow, R. Subunit-specific rules governing 
AMPA receptor trafficking to synapses in hippocampal pyramidal neurons. Cell 105, 
331-43 (2001). 
8. Luscher, C. et al. Role of AMPA receptor cycling in synaptic transmission and 
plasticity. Neuron 24, 649-58 (1999). 
9. Nishimune, A. et al. NSF binding to GluR2 regulates synaptic transmission. Neuron 
21, 87-97 (1998). 
10. Song, I. et al. Interaction of the N-ethylmaleimide-sensitive factor with AMPA 
receptors. Neuron 21, 393-400 (1998). 
11. Hayashi, Y. et al. Driving AMPA receptors into synapses by LTP and CaMKII: 
requirement for GluR1 and PDZ domain interaction. Science 287, 2262-7 (2000). 
12. Carlisle, H.J. & Kennedy, M.B. Spine architecture and synaptic plasticity. Trends 
Neurosci 28, 182-7 (2005). 
13. Karcher, R.L., Deacon, S.W. & Gelfand, V.I. Motor-cargo interactions: the key to 
transport specificity. Trends Cell Biol 12, 21-7 (2002). 
14. Osterweil, E., Wells, D.G. & Mooseker, M.S. A role for myosin VI in postsynaptic 
structure and glutamate receptor endocytosis. J Cell Biol 168, 329-38 (2005). 
15. Lise, M.F. et al. Involvement of myosin Vb in glutamate receptor trafficking. J Biol 
Chem 281, 3669-78 (2006). 
16. Triller, A. & Choquet, D. Surface trafficking of receptors between synaptic and 
extrasynaptic membranes: and yet they do move! Trends Neurosci 28, 133-9 (2005). 
17. Mercer, J.A., Seperack, P.K., Strobel, M.C., Copeland, N.G. & Jenkins, N.A. Novel 
myosin heavy chain encoded by murine dilute coat colour locus. Nature 349, 709-13 
(1991). 
18. Naisbitt, S. et al. Interaction of the postsynaptic density-95/guanylate kinase domain-
associated protein complex with a light chain of myosin-V and dynein. J Neurosci 20, 
4524-34 (2000). 
19. Walikonis, R.S. et al. Identification of proteins in the postsynaptic density fraction by 
mass spectrometry. J Neurosci 20, 4069-80 (2000). 
20. Yoshimura, A. et al. Myosin-Va facilitates the accumulation of mRNA/protein 
complex in dendritic spines. Curr Biol 16, 2345-51 (2006). 
21. Pastural, E. et al. Griscelli disease maps to chromosome 15q21 and is associated 
with mutations in the myosin-Va gene. Nat Genet 16, 289-92 (1997). 
22. Sanal, O. et al. An allelic variant of Griscelli disease: presentation with severe 
hypotonia, mental-motor retardation, and hypopigmentation consistent with Elejalde 
syndrome (neuroectodermal melanolysosomal disorder). J Neurol 247, 570-2 
(2000). 
23. Tabb, J.S., Molyneaux, B.J., Cohen, D.L., Kuznetsov, S.A. & Langford, G.M. 
Transport of ER vesicles on actin filaments in neurons by myosin V. J Cell Sci 111 ( 
Pt 21), 3221-34 (1998). 
24. Takagishi, Y. et al. The dilute-lethal (dl) gene attacks a Ca2+ store in the dendritic 
spine of Purkinje cells in mice. Neurosci Lett 215, 169-72 (1996). 
25. Petralia, R.S. et al. Glutamate receptor targeting in the postsynaptic spine involves 
mechanisms that are independent of myosin Va. Eur J Neurosci 13, 1722-32 (2001). 
26. Miyata, M. et al. Local calcium release in dendritic spines required for long-term 
synaptic depression. Neuron 28, 233-44 (2000). 
27. Schnell, E. & Nicoll, R.A. Hippocampal synaptic transmission and plasticity are 
preserved in myosin Va mutant mice. J Neurophysiol 85, 1498-501 (2001). 
28. Van Zundert, B., Yoshii, A. & Constantine-Paton, M. Abnormally large AMPA 
receptor currents in flailer mutant mice. Society for Neuroscience Abstract 
493.20(2005). 
29. Wenthold, R.J., Petralia, R.S., Blahos, J., II & Niedzielski, A.S. Evidence for multiple 
AMPA receptor complexes in hippocampal CA1/CA2 neurons. J Neurosci 16, 1982-
9 (1996). 
30. Ullrich, O., Reinsch, S., Urbe, S., Zerial, M. & Parton, R.G. Rab11 regulates 
recycling through the pericentriolar recycling endosome. J Cell Biol 135, 913-24 
(1996). 
31. Brown, J.R., Simonetta, K.R., Sandberg, L.A., Stafford, P. & Langford, G.M. 
Recombinant globular tail fragment of myosin-V blocks vesicle transport in squid 
nerve cell extracts. Biol Bull 201, 240-1 (2001). 
32. Lapierre, L.A. et al. Myosin vb is associated with plasma membrane recycling 
systems. Mol Biol Cell 12, 1843-57 (2001). 
33. Rodriguez, O.C. & Cheney, R.E. Human myosin-Vc is a novel class V myosin 
expressed in epithelial cells. J Cell Sci 115, 991-1004 (2002). 
34. Zhu, J.J., Esteban, J.A., Hayashi, Y. & Malinow, R. Postnatal synaptic potentiation: 
delivery of GluR4-containing AMPA receptors by spontaneous activity. Nat Neurosci 
3, 1098-106 (2000). 
35. Watt, A.J., van Rossum, M.C., MacLeod, K.M., Nelson, S.B. & Turrigiano, G.G. 
Activity coregulates quantal AMPA and NMDA currents at neocortical synapses. 
Neuron 26, 659-70 (2000). 
36. Gerges, N.Z., Brown, T.C., Correia, S.S. & Esteban, J.A. Analysis of Rab protein 
function in neurotransmitter receptor trafficking at hippocampal synapses. Methods 
Enzymol 403, 153-66 (2005). 
37. Ehrlich, I. & Malinow, R. Postsynaptic density 95 controls AMPA receptor 
incorporation during long-term potentiation and experience-driven synaptic plasticity. 
J Neurosci 24, 916-27 (2004). 
38. Piccini, A. & Malinow, R. Critical postsynaptic density 95/disc large/zonula 
occludens-1 interactions by glutamate receptor 1 (GluR1) and GluR2 required at 
different subcellular sites. J Neurosci 22, 5387-92 (2002). 
39. Ryu, J. et al. A critical role for myosin IIb in dendritic spine morphology and synaptic 
function. Neuron 49, 175-82 (2006). 
40. Park, M., Penick, E.C., Edwards, J.G., Kauer, J.A. & Ehlers, M.D. Recycling 
endosomes supply AMPA receptors for LTP. Science 305, 1972-5 (2004). 
41. Brown, T.C., Correia, S.S., Petrok, C.N. & Esteban, J.A. Functional 
compartmentalization of endosomal trafficking for the synaptic delivery of AMPA 
receptors during long-term potentiation. J Neurosci 27, 13311-5 (2007). 
42. Seabra, M.C. & Coudrier, E. Rab GTPases and myosin motors in organelle motility. 
Traffic 5, 393-9 (2004). 
43. Jordens, I., Marsman, M., Kuijl, C. & Neefjes, J. Rab proteins, connecting transport 
and vesicle fusion. Traffic 6, 1070-7 (2005). 
44. Krementsov, D.N., Krementsova, E.B. & Trybus, K.M. Myosin V: regulation by 
calcium, calmodulin, and the tail domain. J Cell Biol 164, 877-86 (2004). 
45. Lynch, G., Larson, J., Kelso, S., Barrionuevo, G. & Schottler, F. Intracellular 
injections of EGTA block induction of hippocampal long-term potentiation. Nature 
305, 719-21 (1983). 
46. Cao, T.T., Chang, W., Masters, S.E. & Mooseker, M.S. Myosin-Va binds to and 
mechanochemically couples microtubules to actin filaments. Mol Biol Cell 15, 151-61 
(2004). 
47. Ali, M.Y. et al. Myosin Va maneuvers through actin intersections and diffuses along 
microtubules. Proc Natl Acad Sci U S A 104, 4332-6 (2007). 
48. Huang, J.D. et al. Direct interaction of microtubule- and actin-based transport 
motors. Nature 397, 267-70 (1999). 
49. Mehta, A.D. et al. Myosin-V is a processive actin-based motor. Nature 400, 590-3 
(1999). 
50. Dunah, A.W. et al. LAR receptor protein tyrosine phosphatases in the development 
and maintenance of excitatory synapses. Nat Neurosci 8, 458-67 (2005). 
 
 
FIGURE LEGENDS 
 
Figure 1. Myosin Va associates with AMPA receptors through the GluR1 C-
terminus. a. Silver staining of AMPARs and co-immunopurified proteins from 
hippocampal neurons. Immunopurification was carried out with an anti-GluR2 C-
terminus antibody or with a non-immune IgG, as control. Myosin Va was identified by 
mass spectroscopy. b. Coimmunoprecipitation between AMPARs and associated 
proteins using anti-GluR1 and –GluR2 antibodies. Non-immune IgG and anti-NR1 
antibodies were used as control. c. Left: Western blot analysis of AMPA receptor 
subunits from hippocampal neurons pulled-down with the medial (“GST-M”) or globular 
(“GST-G”) tail of Myosin Va fused to GST. Plain GST was used as control. Middle: 
Similar GST pull-downs using extracts from COS-7 cells expressing full-length myc-
tagged GluR1, a myc-tagged GluR1 mutant lacking the last 30 amino acids, or EGFP-
tagged Rab11, as indicated. Anti-myc antibodies were used to detect recombinant 
GluR1, and anti-GFP for recombinant Rab11. Right: His-tagged GluR1 C-terminus (last 
50 amino acids) was expressed in COS-7 cells and purified through a nickel-column. 
The purified recombinant protein was used for pull-down with GST or GST-Myosin Va 
globular tail. Anti-His antibodies were used to detect pulled-down GluR1 C-terminus. 
Lower panels: Coomassie staining of GST fusion proteins used in the pull-downs. 
 
Figure 2. Subcellular distribution of Myosin Va in neurons and partial 
colocalization with synaptic proteins. a, b. Co-immunofluorescence labeling of 
GluR2 (A) and GluR1 (B) (left panels) with Myosin Va (middle panels) in primary 
hippocampal neurons. Overlay in right panels. Higher magnification of dendritic 
branches in lower panels. c, d. Co-immunofluorescence labeling of PSD95 (C) and 
actin (D) (left panels) with Myosin Va (middle panels) in hippocampal slices. Overlay in 
right panels. Smaller panels on the right show higher magnification images of dendritic 
branches. Scale bars represent 2 μm. 
 
Figure 3. Myosin Va-dn-mediated depression of AMPA and NMDA currents is 
dependent on spontaneous activity. Organotypic slice cultures were infected with 
GFP-tagged Myosin Va-dn or Myosin VI-dn, as indicated. Some slices were incubated 
in 12 mM MgCl2 (“high Mg2+”) or 1 μM tetrodotoxin (“TTX”) during the expression of the 
recombinant protein to block spontaneous activity, as indicated. Double whole-cell 
recordings were established from pairs of uninfected and infected CA1 neurons under 
voltage-clamp configuration. The amplitude of the evoked postsynaptic response 
mediated by AMPA (a), NMDA (b) or GABAA receptors (c) was normalized to the 
uninfected neurons for each experimental condition and plotted as averages ± standard 
error of the mean. d. Presynaptic function was evaluated by monitoring paired-pulse 
facilitation at different interstimulus intervals (50, 100, 200, and 400 ms) in uninfected 
neurons and neurons expressing GFP-Myosin Va-dn. Paired-pulse facilitation was 
calculated as the ratio between the amplitude of the second response versus the 
amplitude of the first response. Insets, Sample trace of evoked AMPA receptor-
mediated synaptic responses with an interstimulus interval of 100 ms. Error bars 
represent standard error of the mean in all figures. “n” represents the number of cells. 
Statistical significance was determined by using the Wilcoxon test for paired data (a−c) 
and by the Mann-Whitney test for unpaired data (d). 
 
Figure 4. Myosin Va does not participate in constitutive receptor cycling, but it is 
required for LTP and CaMKII-mediated synaptic delivery of GluR1. a. Time course 
of AMPAR-mediated responses recorded from CA1 neurons expressing Myosin Va-dn 
(solid symbols) or uninfected neurons (empty symbols), during whole-cell pipette 
infusion of pep2m. Responses are normalized to a 2 min baseline from the beginning of 
the recording. Inset: sample traces from baseline (thick lines) and 25-30 min average 
(thin lines). b. Average remaining current after 25-30 min recording from the time 
courses shown in a, and from similar experiments in which the control peptide, pep4c, 
was used. P values indicate statistical significance with respect to a 2 min baseline from 
the beginning of the recordings. c. LTP was induced in CA1 neurons infected with virus 
expressing GFP-Myosin Va-dn (black squares), transfected with anti-Myosin Va siRNA 
(grey squares) or untransfected neurons (empty symbols). Slices were incubated in 12 
mM MgCl2 or 1 μM tetrodotoxin during transfection to prevent depression of basal 
AMPAR and NMDAR responses (similar results were obtained with both treatments, 
and the data were pooled together). Inset, sample trace of evoked AMPA receptor-
mediated synaptic responses recorded at –60 mV before pairing (thick line) and 30 min 
after pairing (thin line). d. Normalized average potentiation of AMPAR-mediated 
responses collected between 25 and 30 min of the time course shown in c. Paired 
(LTP) and unpaired (control) pathways are shown. e. AMPAR mediated responses were 
recorded at -60 mV and + 40 mV. The rectification index (RI) was calculated as the ratio 
of responses at these holding potentials. Sample traces are shown above the 
corresponding columns of the plot. f. Similar experiments as the one shown in e were 
carried out using a specific siRNA against Myosin Va or a scrambled (control) siRNA. 
Sample traces are shown above the corresponding columns of the plot. 
 
Figure 5. Myosin Va is not required for the trafficking of AMPA receptors into 
distal apical dendrites. Hippocampal slices in culture were co-transfected with GFP-
GluR1 (a−c) or GFP-GluR2 (D-F), together with tCaMKII and RFP-tagged Myosin Va-dn 
or Myosin Vb-dn, as indicated. a, d. Representative confocal images of transfected CA1 
neurons. b, e. GFP-AMPAR fluorescence intensity along the primary apical dendrite 
was normalized to the maximum fluorescence (peak of fluorescence observed in the 
soma of neuron) and plotted as a function of the distance from the cell body. Average 
values are represented for each condition (number of analyzed cells is indicated in c 
and f). c, f. Normalized average fluorescence at distal apical dendrites calculated 
between 100 μm and 200 μm from the soma, for GFP-GluR1 (c) and GFP-GluR2 (f) 
transfected cells. Some GFP-GluR2 cells were treated with 50 nM vincristine during the 
expression time (this treatment does not affect the dendritic distribution of cytosolic 
RFP; not shown). “n” represents number of cells. Statistical significance was calculated 
with Mann-Whitney test. 
 
Figure 6. Myosin Va-dn specifically impairs the translocation of GluR1 receptors 
from dendrites into spines. a−c. Hippocampal CA1 neurons were transfected with 
GFP-GluR1 or GFP-GluR1 plus tCamKII, together with RFP, RFP-Myosin Va-dn or 
RFP-Myosin Vb-dn, as indicated. a. Representative confocal images of spines (arrows) 
and the adjacent dendritic shafts from neurons transfected with GFP-GluR1 and 
tCaMKII, together with RFP (top) or RFP-Myosin Va-dn (bottom), as indicated. Scale 
bar: 1 µm. b. Average GFP-GluR1 fluorescence intensity in spines was normalized to 
GFP fluorescence in the adjacent dendrite for each experimental condition. “n” 
represents number of spine-dendrite pairs from 10 neurons in each condition. c. 
Cumulative distributions of spine/dendrite ratios from the same data plotted in b: “GFP-
GluR1 + RFP” (dashed line), “GFP-GluR1 + tCaMKII + RFP” (black line), “GFP-GluR1 + 
tCaMKII + RFP-Myosin Va-dn” (red line), “GFP-GluR1 + tCaMKII + RFP-Myosin Vb-dn” 
(grey line). Statistical significance is expressed with respect to the “GFP-GluR1 + 
tCaMKII + RFP” distribution, according to the Kolmogorov-Smirnov test. d, e. Similar to 
a, b, with CA1 hippocampal neurons transfected with GFP-GluR2 together with RFP, 
RFP-Myosin Va-dn or RFP-Myosin Vb-dn, as indicated. “n” represents number of spine-
dendrite pairs from 10 (RFP) or 11 (RFP-Myosin-dn) neurons. f. Cumulative 
distributions of spine/dendrite ratios from the same data plotted in e: “GFP-GluR2 + 
RFP” (black line), “GFP-GluR2 + RFP-Myosin Va-dn” (red line), “GFP-GluR2 + RFP-
Myosin Vb-dn” (grey line). Statistical significance is expressed with respect to the “GFP-
GluR2 + RFP” distribution, according to the Kolmogorov-Smirnov test. 
 
Figure 7. Myosin Va is not required for the trafficking of PSD95 into spines or for 
spine morphology. a−c. Hippocampal CA1 neurons were transfected with PSD95-GFP 
together with RFP or RFP-Myosin Va-dn. a. Representative confocal images of dendritic 
branches from neurons transfected with PSD95-GFP plus RFP (left) or RFP-Myosin Va-
dn (right), as indicated. Scale bar: 5 µm. b. Average PSD95-GFP fluorescence intensity 
in spines was normalized to GFP fluorescence in adjacent dendrite for each 
experimental condition, as indicated. c. Cumulative distributions of spine/dendrite ratios 
from the same data plotted in b. Statistical significance was calculated according to the 
Kolmogorov-Smirnov test. “n” represent number of spine-dendrite pairs. d, e. Similar to 
a, c, with CA1 hippocampal neurons co-transfected with GFP together with RFP or 
RFP-Myosin Va-dn, as indicated. GFP is used as a volume indicator. “n” represents 
number of spine-dendrite pairs. Scale bar: 1 µm. f, g. Spine length (f) and spine density 
(g) were determined using PSD95-GFP fluorescence as a spine marker. “n” is the 
number of spines (f) or dendritic branches (g). Statistical significance was determined 
by the Mann-Whitney test for unpaired data. 
 
Figure 8. Myosin Va-dn impairs the translocation of Rab11 from dendrites into 
spines and Rab11 facilitates the interaction of GluR1 with the Myosin Va globular 
tail. a. Representative confocal images of CA1 hippocampal neurons transfected with 
GFP-Rab11 and RFP (top) or GFP-Rab11 plus RFP-Myosin Va-dn (bottom). Scale bar: 
2 µm. b. GFP-Rab11 fluorescence was quantified and plotted as cumulative 
distributions of spine/dendrite ratios of GFP fluorescence, as described for Figs. 6 and 
7. “n” represent number of spine-dendrite pairs from 10 neurons in each condition. 
Statistical significance was calculated using the Kolmogorov-Smirnov test. c. Whole 
extracts of BHK cells separately expressing GFP, GFP-Rab11, GFP-GluR1 and GFP-
Myosin Va globular tail (GFP-MyoVa-GT) were combined, as indicated (GFP-MyoVa-
GT was present in all combinations). Proteins were incubated in the presence of non-
hydrolizable GTP (GMP-PNP; Sigma) or GDP, and immunoprecipitated with an anti-
GluR1 antibody. Samples were then analyzed by western blotting with an anti-GFP 
antibody. The presence of GFP, GFP-GluR1 and GFP-Myosin Va-GT in the 
immunoprecipitated fraction is indicated in the figure. Western blot shows a 
representative example from 4 independent experiments. 
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SUPPLEMENTARY INFORMATION 
 
METHODS 
Fluorescence imaging 
Primary hippocampal neurons (DIV21) or organotypic hippocampal slices were 
fixed with 4% paraformaldehyde plus 4% sucrose and processed for imunostaining. 
Primary antibodies were rabbit anti-Myosin Va (Sigma), and mouse anti-GluR1 
(Epitomics), anti-GluR2 (Chemicon), anti-PSD95 (Upstate) and anti-actin (Chemicon). 
Secondary antibodies were anti-rabbit conjugated to Alexa 594 and anti-mouse 
conjugated to Alexa 488. Images were obtained with an Olympus FV500 confocal 
microscope with a 60x oil immersion lens. Digital images were acquired using the 
FluoView software and were reconstructed and analyzed using Image J software. 
Dendritic and spine distributions of GFP-tagged proteins was quantified as previously 
described36. 
 
Preparation of hippocampal extracts and Western blot analysis 
Hippocampal slices from organotypic cultures were homogenized in 10 mM HEPES, pH 
7.4, 500 mM NaCl, 10 mM NaF, 1 µM Microcystin LR, 0.5 µM Calyculin A, 10 mM EDTA, 
0.1 mM PMSF, 2 µg/ml CLAP (cocktail of Chymostatin, Leupeptin, Pepstatin A and 
Antipain) and 1% Triton X-100. Insoluble fraction was discarded and soluble fraction 
samples were denatured and resolved by SDS-PAGE. Primary antibodies for Western 
blot analysis were from Chemicon (GluR1, GluR1 phospho-S831, GluR2/3, NR2B, 
αCamKII phospho-T286 and actin), Sigma (Myosin Va), Upstate (PSD95 and αCamKII), 
BD Biosciences (Rab8 and Rab11), Santa Cruz (GKAP) and Roche (GFP). 
 
Supplementary Figure 1. Myosin Vb-dn does not affect AMPAR-mediated synaptic 
transmission. Organotypic slice cultures were infected with GFP-tagged Myosin Vb-dn, 
Double whole-cell recordings were established from pairs of uninfected and infected 
CA1 neurons under voltage-clamp configuration. The amplitude of the evoked 
postsynaptic response mediated by AMPA or NMDA receptors was normalized to the 
uninfected neurons and plotted as averages ± standard error of the mean. “n” represents 
number of cell pairs. To note, Myosin Vb-dn produced a significant depression of 
NMDAR-mediated currents, which we have not explored further. 
 
Supplementary Figure 2. Myosin Va-dn does not affect expression of several 
synaptic proteins in CA1 hippocampal neurons. Extracts of CA1 regions from 
organotypic hippocampal slices uninfected or infected with GFP-Myosin Va-dn were 
resolved by SDS-PAGE and analyzed by Western blotting. A. Average immunoreactivity 
of each indicated protein from infected slices was normalized to the control (uninfected) 
condition and plotted as a percentage ± standard error of the mean (n>6 for each 
protein). Values for phosphorylated proteins (GluR1 P-S831 and αCaMKII P-T286) were 
divided by the total levels of the corresponding protein B. Representative western blots 
for the data shown in A. 
 
Supplementary Figure 3. Characterization of a specific siRNA against Myosin Va. 
A. COS-7 cells were transfected with GFP-tagged Myosin Va globular tail (aa 1005-
1830) together with an anti-Myosin Va small interference RNA (MyoVa siRNA), a 
scrambled siRNA or pSuper empty vector (see Methods for specific sequences). Cell 
extracts were prepared 24 hours after transfection and were analyzed by western blot 
using antibodies against GFP (top panel) or actin (bottom panel). Histogram: 
Quantification of Myosin Va globular tail expression from three independent 
experiments as the one shown above. MyoVa siRNA produced a significant 
suppression of Myosin Va as compared to the empty vector (p=0.04) and the scramble 
siRNA (p=0.01) B. Hippocampal neurons (DIV 3) were transfected with GFP and either 
with anti-MyoVa siRNA or scrambled siRNA. Four days after transfection, neurons were 
fixed and stained for endogenous Myosin Va. Reduction in Myosin Va staining is 
apparent in neurons transfected with anti-MyoVa siRNA (right panels; arrowhead) but 
not with the scramble siRNA (left panels; arrowhead). Scale bar, 10 µm. C. 
Quantification of endogenous Myosin Va expression from experiments as the one 
shown in C, after 2 days (left) or 4 days (right) of siRNA expression. Levels of Myosin 
Va staining intensity were normalized to untransfected neurons in the same field. Anti-
MyoVa siRNA significantly reduced the expression levels of endogenous Myosin Va 
after both 2 and 4 days (p=0.002 and p<0.0001, respectively). 
 
Supplementary Figure 4. Myosin Va is required for PSD95-driven synaptic 
delivery of GluR1. AMPAR mediated responses were recorded at -60 mV and + 40 
mV. The rectification index (RI) was calculated as the ratio of responses at these 
holding potentials. RI was determined for untransfected CA1 neurons and for neurons 
transfected with GFP-GluR1 plus PSD95 (A), or GFP-GluR1 plus PSD95 and GFP-
tagged Myosin Va-dn (B). “n” represents number of cells. Statistical significance was 
calculated with Mann-Whitney test. Sample traces are shown above the corresponding 
columns of the plot. 
 
Supplementary Figure 5. Schematic model for the role of Myosin Va and Rab11 in 
the regulated delivery of AMPA receptors into spines. Left part (“constitutive”) 
depicts the continuous (activity-independent) delivery of GluR2/GluR3 receptors, which 
does not require Myosin Va. Right part (“LTP”) represents the activity-dependent 
translocation of GluR1/GluR2 receptors mediated by Myosin Va and Rab11. In this 
case, receptor transport may be triggered by Myosin Va activation upon NMDAR 
activation and Ca2+ entry, or by specific modifications in the GluR1 subunit that enable it 
to associate with the motor complex (see further explanations in the main text). As 
recently reported, final synaptic delivery after receptor entry into the spine is thought to 
be mediated by a different endosomal compartment, controlled by Rab841. Myosin Va 
motor and cargo binding domains are represented in pink and blue, respectively. 
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